When was RayThera founded?

RayThera was founded in 2023 and raised its 1st funding round 2 years after it was founded.

Where is RayThera located?

RayThera is headquartered in San Diego, United States.

Who is the current CEO of RayThera?

Qing Dong of RayThera. They have also founded 1 company.

Is RayThera a funded company?

RayThera is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Apr 04, 2025.

When was the latest funding round of RayThera?

RayThera's latest funding was a $***** Series A round on Apr 04, 2025, with participation from 3 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.27B in funding in 2026 to date.

Where does RayThera rank among its competitors?

RayThera ranks 23rd amongst 316 active competitors, of which 114 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Trimtech Therapeutics, which secured $14M in Jun, 2026.

Who are the top competitors of RayThera?

RayThera's top competitors include Upstream Bio, Odyssey and Septerna. Among them, Trimtech Therapeutics secured the most recent funding round in June, 2026.

RayThera - 2026 Company Profile, Team, Funding & Competitors

Q: Is RayThera an acquired company?

RayThera got acquired by Biogen on Jun 17, 2026.

RayThera is an acquired company based in San Diego (United States), founded in 2023 by Gene Hung and Qing Dong. It operates as a Developer of small molecule therapies for unmet needs in immunology. RayThera has raised $110M in funding from Foresite Capital. The company has 316 active competitors, including 114 funded and 62 that have exited. Its top competitors include companies like Upstream Bio, Odyssey and Septerna.

Company Details

Developer of small molecule therapies for unmet needs in immunology. This company specializes in advancing drug discovery, leveraging proven expertise to accelerate the development process while maintaining rigorous standards. The focus is on creating transformative therapies to improve patient care. Their approach centers on developing breakthrough small molecule treatments addressing critical unmet needs within the immunology field.

Website: www.raythera.com/
Email ID: *****@raythera.com

Key Metrics

Founded Year

2023

Location

San Diego, United States

Stage

Acquired

Total Funding

$110M in 1 round

Latest Funding Round

Series A, Apr 04, 2025, $*****

Investors

Foresite Capital & 2 more

Ranked

23^rd among 316 active competitors

Similar Companies

Upstream Bio & 378 more

Exit Details

Acquired by Biogen (Jun 17, 2026)

View RayThera's full profile

RayThera got acquired by Biogen on Jun 17, 2026 at an acquisition amount of $*****.

Click here to take a look at RayThera's acquisition in detail

RayThera has raised a total funding of $110M over 1 round. Its latest funding round was a Series A round on Apr 04, 2025 for $*****. 3 investors participated in its latest round. RayThera has 3 institutional investors.

Here is the list of recent funding rounds of RayThera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 04, 2025	1673876	Series A	5012698	8028402	1556478	1400247

Access funding benchmarks and valuations. Sign up today!

View details of RayThera's funding rounds and investors

The founders of RayThera are Gene Hung and Qing Dong. Qing Dong is the CEO of RayThera.

Here are the details of RayThera's key team members:

Gene Hung: Co-Founder & CSO of RayThera.
Contact Info: 2 email addresses
Qing Dong: Co-Founder & CEO of RayThera.

View details of RayThera's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RayThera include Upstream Bio, Odyssey and Septerna. Here is the list of Top 10 competitors of RayThera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	67/100
2nd	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
3rd	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
4th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
5th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
6th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
7th	Vyome Therapeutics 2010, Princeton (United States), Public	Developer of therapeutics for the immuno-inflammatory conditions	$62.9M	Perceptive Advisors, Iron Pillar & 11 others	64/100
8th	Trimtech Therapeutics 2023, Cambridge (United Kingdom), Seed	They develop treatments for CNS and inflammatory disorders	$47M	Cambridge Innovation Capital, SV Health Investors ... & 11 others	61/100
9th	Emmaus Medical 2000, Torrance (United States), Acquired	Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia	-	E&Investment, Mitsubishi UFJ Capital & 4 others	60/100
10th	Equillium 2017, San Diego (United States), Public	Developer of therapies for treating autoimmune and inflammatory disorders	-	ADAR1 Capital Management, Janus Henderson Investors ... & 6 others	60/100
23rd	RayThera 2023, San Diego (United States), Acquired	Developer of small molecule therapies for unmet needs in immunology	$110M	Foresite Capital, Orbimed & 1 others	55/100